Have received an investigational or approved vaccine for COVID-19  

Have participated in another study within the past month

Moderna is studying a potential vaccine for the prevention of cytomegalovirus (also called CMV). Clinical research studies and the volunteers who take part in research studies are vital to creating vaccines that will safely protect people from all ages and backgrounds against viruses.
The purpose of this research study is to understand how the body responds to different doses of the mRNA-1647 investigational vaccine that may protect women against CMV. This study will specifically look for any side effects of the vaccine and whether or not an immune response is generated. Results from this study will be used to select the best dose of the mRNA-1647 vaccine to be used in future studies.


A Clinical Trial of a Cytomegalovirus (CMV) Vaccine in Adults

A Clinical Study of a Cytomegalovirus (CMV) Vaccine in Adults

Have tested positive for COVID-19 or been in contact with anyone diagnosed with COVID-19 within 2 weeks prior to study vaccine administration

Have participated in another trial in the past month

Have participated in another study in the past month

Be between the ages of 12 and 59 months (1 – less than 5 years old)

Have received routine immunizations appropriate for their age

This study is evaluating an investigational combination vaccine, called mRNA-1653, to protect against hMPV and PIV3. Both hMPV and PIV3 are known to cause respiratory disease in people of all ages, often in children.

This study will evaluate the safety and immune responses of the mRNA-1653 vaccine when administered to children ages 1 year and less than 5 years of age who have previously had an infection with both hMPV and PIV3 (this could have been just what seemed like a mild common cold).

There are no approved vaccines to prevent hMPV or PIV3 infections. A safe and effective vaccine against hMPV and PIV3 has the potential to substantially improve the health of young children.


A Clinical Trial of a Human Metapneumonovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine in Healthy Adults and Children

A Clinical Study of a Human Metapneumonovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine in Healthy Adults and Children

Have tested positive for COVID-19 or been in contact with anyone diagnosed with COVID-19 within 30 days prior to study vaccine administration

Have travelled outside of the United States within the last 28 days prior to screening for the study 

Be receiving treatment with investigational agents for prevention of COVID-19 or treatment of COVID-19 

Be at least 18 years old and no older than 55 years

Researchers in the mRNA-1283-P101 study are testing if the mRNA-1283 investigational vaccine may be effective in preventing COVID-19. 

The study is enrolling individuals who are 18-55 years old and are in good health. Participants in the study will receive either the mRNA-1283 study vaccine or the mRNA-1273 vaccine. mRNA-1283 is not currently authorized for preventing COVID-19. 

A Clinical Trial of a COVID-19 Vaccine in Healthy Adults

A Clinical Study of a COVID-19 Vaccine in Healthy Adults

An Observational Study of a COVID-19 Vaccine in Pregnant Women

Have participated in another clinical trial in the past month

Have participated in another clinical study in the past month

Have received any vaccine in the past month, or plan to in the next month (other than a COVID-19 vaccination)

Have received a seasonal flu shot in the past 6 months

Be in generally good health, with any chronic conditions well-controlled

The mRNA-1010-P101 clinical trial is evaluating if an investigational mRNA vaccine is safe and effective in preventing the flu in adults. 

Current seasonal flu vaccines are usually only 60% effective at best, and they often perform poorly during years when the circulating flu strains don’t match the strains selected for that year’s vaccine. Flu vaccines based on mRNA technology could potentially provide several benefits compared to current vaccines, including the ability to respond to changes in influenza strains more quickly, stronger immune responses, and improved protection in older adults.


The mRNA-1010-P101 clinical study is evaluating if an investigational mRNA vaccine is safe and effective in preventing the flu in adults. 

Current seasonal flu vaccines are usually only 60% effective at best, and they often perform poorly during years when the circulating flu strains don’t match the strains selected for that year’s vaccine. Flu vaccines based on mRNA technology could potentially provide several benefits compared to current vaccines, including the ability to respond to changes in influenza strains more quickly, stronger immune responses, and improved protection in older adults.


A Clinical Trial of a Seasonal Flu Vaccine in Healthy Adults

A Clinical Study of a Seasonal Flu Vaccine in Healthy Adults

A Clinical Trial of a Zika Vaccine in Healthy Adults

A Clinical Study of a Zika Vaccine in Healthy Adults

Cancer is a major public health problem and is the leading cause of death worldwide. Due to increased screening and targeted treatment regimens, there has been a trend over the past decade toward a slowing or halting in the progression of some highly preventable cancers (e.g. lung and skin cancers). However, there remains an unmet need for targeted anticancer therapies, especially for patients for whom current treatments have not been effective.  

Have active central nervous system metastases and/or carcinomatous meningitis

During the trial, participants will attend up to 54 visits to the trial site over the course of approximately 5 years.  

Participants in this trial will be assigned to receive mRNA-4157 on its own or both mRNA-4157 and pembrolizumab. 

The trial will consist of a dose escalation phase and an expansion phase. The objective of the dose escalation phase is to determine the dosage of mRNA-4157, while the expansion phase will further evaluate the safety of the dosage identified in the dose escalation phase.

mRNA-4157 will be administered as an injection into the tumor, while pembrolizumab will be administered as an intravenous infusion. 

Every clinical trial participant will receive the same level of quality care regardless of which treatment group they are assigned.  

Insurance is not needed to join this trial, and all trial-related medications are provided at no cost to participants. 


During the study, participants will attend up to 54 visits to the study site over the course of approximately 5 years.  

Participants in this study will be assigned to receive mRNA-4157 on its own or both mRNA-4157 and pembrolizumab. 

The study will consist of a dose escalation phase and an expansion phase. The objective of the dose escalation phase is to determine the dosage of mRNA-4157, while the expansion phase will further evaluate the safety of the dosage identified in the dose escalation phase.

mRNA-4157 will be administered as an injection into the tumor, while pembrolizumab will be administered as an intravenous infusion. 

Every clinical study participant will receive the same level of quality care regardless of which treatment group they are assigned.  

Insurance is not needed to join this study, and all study-related medications are provided at no cost to participants. 


The mRNA-4157-P101 Trial is a Phase 1 clinical trial evaluating the safety, tolerability, and immunogenicity of an investigational mRNA personal cancer vaccine, called mRNA-4157, in adults with solid tumors. The clinical trial will study both mRNA-4157 on its own and when used in combination with pembrolizumab (an approved immunotherapy treatment, also known as KEYTRUDA®). 

mRNA-4157 is an investigational personalized cancer vaccine, meaning each patient’s exact treatment is unique to them. To do this, researchers analyze the patient’s healthy genes and genes from their tumor to identify up to 34 mutations that may help their immune system launch the strongest attack against the tumor. Based on these mutations, instructions are created and then loaded onto a single molecule of messenger RNA, or mRNA, designed to tell the patient's body how to fight their cancer. The goal is that this design of the personalized cancer vaccine will inform the immune system to attack and destroy only the tumor cells.


The mRNA-4157-P101 Study is a Phase 1 clinical study evaluating the safety, tolerability, and immunogenicity of an investigational mRNA personal cancer vaccine, called mRNA-4157, in adults with solid tumors. The clinical study will study both mRNA-4157 on its own and when used in combination with pembrolizumab (an approved immunotherapy treatment, also known as KEYTRUDA®). 

mRNA-4157 is an investigational personalized cancer vaccine, meaning each patient’s exact treatment is unique to them. To do this, researchers analyze the patient’s healthy genes and genes from their tumor to identify up to 34 mutations that may help their immune system launch the strongest attack against the tumor. Based on these mutations, instructions are created and then loaded onto a single molecule of messenger RNA, or mRNA, designed to tell the patient's body how to fight their cancer. The goal is that this design of the personalized cancer vaccine will inform the immune system to attack and destroy only the tumor cells.


A Clinical Trial of a Personalized Cancer Vaccine for Adults with Solid Tumors

A Clinical Study of a Personalized Cancer Vaccine for Adults with Solid Tumors

A Clinical Trial of a Treatment Alone and in Combination with Durvaluman in Patients with Advanced Malignancies

A Clinical Study of a Treatment Alone and in Combination with Durvaluman in Patients with Advanced Malignancies

A Clinical Trial of a Chikungunya Vaccine in Healthy Adults

A Clinical Study of a Chikungunya Vaccine in Healthy Adults

A Clinical Trial of a Cytomegalovirus (CMV) Vaccine in Healthy Adults

A Clinical Study of a Cytomegalovirus (CMV) Vaccine in Healthy Adults

A Clinical Trial of a Human metapneumovirus (hMPV) Vaccine in Healthy Adults

A Clinical Study of a Human metapneumovirus (hMPV) Vaccine in Healthy Adults

A Natural History Study of Patients with Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Cancer is a major public health problem and is the leading cause of death worldwide. Due to increased screening and targeted treatment regimens, there has been a trend over the past decade toward a slowing or halting in the progression of some highly preventable cancers (e.g. lung and skin cancers). However, there remains an unmet need for new cancer therapies, especially for patients for whom current treatments have not been effective. 

Have active central nervous system tumors or metastases

Have confirmed advanced or metastatic cancer
- Including triple negative breast cancer, cutaneous melanoma, neoadjuvant melanoma, head and neck squamous cell cancer, Non-Hodgkin’s lymphoma, and non-small cell lung cancer


During the trial, participants will attend in-person visits to the trial site approximately once per month over the course of approximately 2 years. 

Participants in this trial will be assigned to receive either the investigational treatment on its own or the investigational treatment in combination with durvalumab.

The investigational treatment will be administered as an injection into the tumor, while durvalumab will be administered as an intravenous infusion. 

Every clinical trial participant will receive the same level of quality care regardless of which treatment group they are assigned. 

Insurance is not needed to join this trial, and all trial-related medications are provided at no cost to participants.


During the study, participants will attend in-person visits to the study site approximately once per month over the course of approximately 2 years. 

Participants in this study will be assigned to receive either the investigational treatment on its own or the investigational treatment in combination with durvalumab.

The investigational treatment will be administered as an injection into the tumor, while durvalumab will be administered as an intravenous infusion. 

Every clinical study participant will receive the same level of quality care regardless of which treatment group they are assigned. 

Insurance is not needed to join this study, and all study-related medications are provided at no cost to participants.


The mRNA-2752-P101 Trial is a Phase 1 clinical trial evaluating the safety and tolerability of an investigational mRNA cancer treatment, called mRNA-2752, in adults with relapsed or refractory solid tumor malignancies or lymphoma. The investigational treatment is being evaluated on its own and in combination with durvalumab (an approved immunotherapy treatment, also known as IMFINZI®). 

mRNA-2752 is an investigational immuno-oncology treatment, also known as immunotherapy, where the body’s own immune system may be used to treat or prevent cancer. Moderna is pioneering the use of mRNA in immuno-oncology by using the messenger molecule to potentially activate the body’s immune system to attack tumor cells. 


The mRNA-2752-P101 Study is a Phase 1 clinical study evaluating the safety and tolerability of an investigational mRNA cancer treatment, called mRNA-2752, in adults with relapsed or refractory solid tumor malignancies or lymphoma. The investigational treatment is being evaluated on its own and in combination with durvalumab (an approved immunotherapy treatment, also known as IMFINZI®). 

mRNA-2752 is an investigational immuno-oncology treatment, also known as immunotherapy, where the body’s own immune system may be used to treat or prevent cancer. Moderna is pioneering the use of mRNA in immuno-oncology by using the messenger molecule to potentially activate the body’s immune system to attack tumor cells. 


A Clinical Trial of a Cancer Treatment for Adults with Solid Tumor Cancers or Lymphoma

A Clinical Study of a Cancer Treatment for Adults with Solid Tumor Cancers or Lymphoma

A Clinical Trial of a Treatment for Patients with Methylmalonic Acidemia (MMA)

A Clinical Study of a Treatment for Patients with Methylmalonic Acidemia (MMA)

Propionic acidemia, or PA, is a rare organic acid disorder causing metabolic crises, seizures, developmental delays, and more. People who are diagnosed with PA are missing the propionyl-CoA carboxylase (PCC) enzyme, which is responsible for the breakdown of certain proteins and fat. When this enzyme is missing, it is difficult for cells in the body to turn food into energy, leading to toxins building up in the bloodstream. Currently, PA is treated by lowering the amount of protein eaten daily, taking dietary supplements or antibiotics, or getting a liver transplant.

Have a confirmed diagnosis of PA based on diagnosis by molecular genetic testing (PCCA and/or PCCB)

Participation in the Paramount Study will last approximately 3 years and includes approximately 54 visits to a clinical trial site. 
Participation in the Paramount Study consists of 5 parts: 

- __Prescreening period (optional):__ Participants with a diagnosis of PA who have not had genetic testing may have molecular genetic testing performed when the prescreening consent is signed or during the screening period.
- __Screening:__ During this period, which lasts up to 42 days, the clinical trial team will perform tests and procedures to make sure the clinical trial is a good match for the potential participant.
- __Observation period:__ This period lasts 48 to 72 hours. During this period, the clinical trial team will check on the participant’s health, but they will not receive the investigational treatment.
- __Treatment period:__ During this period, the participant will receive the investigational treatment. This period lasts approximately 5 to 10 months (20 to 40 weeks). 
- __Follow-up period:__ This period lasts 2 years after the last dose of the investigational treatment. The participant will enter this part of the clinical trial if they do not continue enrollment in the extension study.

Insurance is not needed to participate, and qualified participants could receive payment for their trial-related time and travel.

The Paramount Study is evaluating whether an investigational treatment, called mRNA-3927, is safe and effective in reducing the symptoms of PA in individuals 1 year of age and older. mRNA-3927 is an investigational intravenous (IV) infusion treatment that instructs a person’s body to make a properly functioning propionyl-CoA carboxylase (PCC) enzyme.

A Clinical Trial of a Propionic Acidemia (PA) Treatment for Children and Adults

Methylmalonic acidemia, or MMA, is a rare organic acid disorder causing metabolic crises, seizures, developmental delays, and more. The most common form of MMA is caused by changes in the gene called the MUT gene. This gene provides instructions for making the MUT enzyme, which is responsible for the proper breakdown of certain proteins and fats. When this enzyme is missing, it is difficult for cells in the body to turn food into energy, leading to toxins building up in the bloodstream. Currently, MMA is treated by lowering the amount of protein eaten daily, taking dietary supplements or antibiotics, or getting an organ transplant.

Have a diagnosis of isolated MMA due to MUT deficiency confirmed by molecular genetic testing

Participation in the Landmark Study will last approximately 3 years and includes approximately 69 visits to a clinical trial site.

Participation in the Landmark Study consists of 5 parts:

- __Prescreening period (optional):__ Participants with a diagnosis of isolated MMA due to MUT deficiency but who have not had genetic testing may have molecular genetic testing performed at any time prior to the screening period. Participants may also have MMA levels drawn during prescreening.
- __Screening:__ During this period, which lasts up to 30 days, the study team will perform tests and procedures to make sure the clinical trial is a good match for the potential participant.
- __Observation period:__ This period lasts 48–72 hours. During this period, the clinical trial team will check on the participant’s health, but the participant will not receive the investigational treatment.
- __Study Treatment period:__ During this period, the participant will receive up to 10 doses of the investigational treatment. This period lasts approximately 9 and a half months (up to 40 weeks).
- __Follow-up period:__ This period lasts 2 years after the last dose of the investigational treatment. The participant will enter this part of the clinical trial OR they can choose to enroll in the [extension study](https://trials.modernatx.com/study/?id=mRNA-3705-P101-EXT) to continue receiving the investigational treatment.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.


The Landmark Study is evaluating whether an investigational treatment, called mRNA-3705, is safe in participants with methylmalonic acidemia (MMA) due to MUT deficiency who are 1 year of age and older. mRNA-3705 is an investigational intravenous (IV) infusion treatment that is intended to instruct a person’s body to make a properly functioning methylmalonyl-coenzyme.

A Clinical Trial of a Methylmalonic Acidemia (MMA) Due to MUT Deficiency Treatment for Children and Adults

A Clinical Study of a Methylmalonic Acidemia (MMA) Due to MUT Deficiency Treatment for Children and Adults

A Clinical Trial of an Autoimmune Therapeutic in Healthy Adults

A Clinical Study of an Autoimmune Therapeutic in Healthy Adults

A Clinical Trial of a Zika Vaccine in Adults

A Clinical Study of a Zika Vaccine in Adults

A Clinical Trial of a COVID-19 Booster Vaccine in Adults

A Clinical Study of a COVID-19 Booster Vaccine in Adults

An Extension Study for Participants in mRNA-1647-P202

A Clinical Trial of a Glycogen Storage Disease Type 1a (GSD1a) Treatment for Adults with mRNA-3745

A Clinical Study of a Glycogen Storage Disease Type 1a (GSD1a) Treatment for Adults with mRNA-3745

A Clinical Trial of a Cytomegalovirus (CMV) Vaccine in Healthy Adults of Japanese Descent

A Clinical Study of a Cytomegalovirus (CMV) Vaccine in Healthy Adults of Japanese Descent

Often vaccines for viruses are made from a weakened or inactive (not live) virus, but the mRNA-1273 study vaccine is different. It is made from an instructional molecule called mRNA that tells your cells how to make protein. In this case, the protein is a small part of the virus that is thought to help the body’s immune system protect itself if you ever come in contact with the coronavirus.

Be receiving treatment with investigational agents for prevention of COVID-19 or treatment of COVID-19

Have received either a kidney transplant or a liver transplant at least six months before screening period

Have received chronic immunosuppressive therapy for the prevention of organ rejection for a minimum of 3 months

Be unvaccinated OR vaccinated with Moderna’s COVID-19 vaccine under the EUA at least two months prior to consent

Participation in the COVE Transplant Study lasts approximately 13 months and includes approximately seven visits to the study site and nine phone calls.

- Participants will have two injection visits, which will happen on Day 1 and on Day 29. 
- Participants will be asked to return to the study site seven days after each injection and then two months, seven months, and 13 months after the first injection. During these study site visits, the study team will monitor for COVID-19 symptoms.
- Participants will be contacted by the study team to monitor for COVID-19 symptoms every four weeks from Day 85 to Day 197, and again from Day 237 to Day 377. During these phone calls, the study team will check how each participant is feeling and ask for updates on their health.
- Participants will also be asked to complete daily eDiary entries for one week after each injection visit. Participants will be asked to complete monthly eDiary entries from Day 71 to Day 183 and from Day 223 to Day 363.

Insurance is not needed to join this trial and compensation for the participant’s time will be available.

Participation in the COVE Transplant Study lasts approximately 13 months and includes approximately seven visits to the study site and nine phone calls.

- Participants will have two injection visits, which will happen on Day 1 and on Day 29. 
- Participants will be asked to return to the study site seven days after each injection and then two months, seven months, and 13 months after the first injection. During these study site visits, the study team will monitor for COVID-19 symptoms.
- Participants will be contacted by the study team to monitor for COVID-19 symptoms every four weeks from Day 85 to Day 197, and again from Day 237 to Day 377. During these phone calls, the study team will check how each participant is feeling and ask for updates on their health.
- Participants will also be asked to complete daily eDiary entries for one week after each injection visit. Participants will be asked to complete monthly eDiary entries from Day 71 to Day 183 and from Day 223 to Day 363.

Insurance is not needed to join this study and compensation for the participant’s time will be available.

Researchers in the COVE Transplant Study are trying to find solutions to the COVID-19 pandemic that can help everyone – including those who have received a kidney or liver transplant.

The purpose of this study is to evaluate an investigational vaccine that may prevent illness after exposure to SARS-CoV-2, which causes COVID-19. There will be two participant groups in this study – a group of individuals who have had a solid organ transplant and are immunocompromised from the transplant, and a control group of individuals who are in good health. The control group is included as a comparison group to help understand how immune cells act after vaccination. Both groups will receive the COVID-19 vaccine.

Unvaccinated solid organ transplant participants will have the option to receive a third dose of the COVID-19 vaccine. Vaccinated solid organ transplant participants will receive a third dose of the COVID-19 vaccine.

A Clinical Trial of a COVID-19 Vaccine in Kidney or Liver Transplant Recipients

A Clinical Study of a COVID-19 Vaccine in Kidney or Liver Transplant Recipients

Respiratory syncytial virus (RSV) can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia, especially in children and older adults. Currently, there is not an approved vaccine for RSV.

Have a history of epilepsy or febrile seizures

For pediatric participants, the total length of participation in this RSV clinical trial lasts approximately 16 months and includes up to 11 clinical trial site visits. 

Pediatric participants will be given 3 injections in the upper arm. Each participant has a chance of receiving either the mRNA-1345 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against RSV. Participants will be closely monitored by the clinic team for any side effects. 

Pediatric participants will have a mix of in-person and phone visits with the trial doctor to monitor for any symptoms after injections. During these visits and phone calls, the clinical trial doctor and medical staff will check how the participant is feeling and ask for updates on their health.

Parents or caregivers of each pediatric participant will be asked to use an eDiary app on their smartphone or a smartphone will be provided to report any symptoms the participant might experience for 7 days after the injection. 
Insurance is not needed to take part in this clinical trial. Compensation for the participant’s trial-related time may be available.

For pediatric participants, the total length of participation in this RSV clinical study lasts approximately 16 months and includes up to 11 clinical study site visits. 

Pediatric participants will be given 3 injections in the upper arm. Each participant has a chance of receiving either the mRNA-1345 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against RSV. Participants will be closely monitored by the clinic team for any side effects. 

Pediatric participants will have a mix of in-person and phone visits with the study doctor to monitor for any symptoms after injections. During these visits and phone calls, the clinical study doctor and medical staff will check how the participant is feeling and ask for updates on their health.

Parents or caregivers of each pediatric participant will be asked to use an eDiary app on their smartphone or a smartphone will be provided to report any symptoms the participant might experience for 7 days after the injection. 
Insurance is not needed to take part in this clinical study. Compensation for the participant’s study-related time may be available.

The mRNA-1345-P101 clinical trial is evaluating the safety and immune response of an investigational vaccine, called mRNA-1345, to protect against Respiratory Syncytial Virus (RSV). 

RSV can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold, and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia especially in children and older adults. Currently there is not an approved vaccine for RSV. 

The mRNA-1345-P101 clinical study is evaluating the safety and immune response of an investigational vaccine, called mRNA-1345, to protect against Respiratory Syncytial Virus (RSV). 

RSV can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold, and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia especially in children and older adults. Currently there is not an approved vaccine for RSV. 

A Clinical Trial of a Respiratory Syncytial Virus (RSV) Vaccine for Adults and Children

A Clinical Study of a Respiratory Syncytial Virus (RSV) Vaccine for Adults and Children

Seasonal influenza is a respiratory illness caused by the influenza virus. This virus infects the lungs and breathing passages and is easily spread from person to person. Every year, seasonal influenza causes 3 to 5 million cases of severe illness and up to 650,000 deaths worldwide. Seasonal influenza more severely affects people 65 years of age and older.

Have participated in another trial within 28 days of the Screening Visit  


Have participated in another study within 28 days of the Screening Visit  


Able to follow participation instructions


Not pregnant or planning on becoming pregnant for at least 3 months following your vaccine visit (as appropriate) 


The total length of participation in this clinical trial is about 13 months and includes up to 3 in-person trial site visits and 6 phone calls to check in about any side effects. 

Participants will be given 1 injection in the upper arm. Each participant has a 50% chance of getting the investigational vaccine and a 50% chance of getting a currently approved seasonal influenza vaccine—like flipping a coin.

After receiving the investigational vaccine, participants must enter information about any influenza symptoms they have had into a symptom-reporting electronic diary, or eDiary. For the first 7 days after the vaccination, participants will be asked to report symptoms daily. Then for the next 6 months, participants will report symptoms twice a week. For the following 6 months, participants will report symptoms once a week. 

Participants will be closely monitored by the clinical trial team for any side effects.  

Insurance is not needed to take part in the Glow Trial. Compensation for the participant’s trial-related time may be available. 


The total length of participation in this clinical study is about 13 months and includes up to 3 in-person study site visits and 6 phone calls to check in about any side effects. 

Participants will be given 1 injection in the upper arm. Each participant has a 50% chance of getting the investigational vaccine and a 50% chance of getting a currently approved seasonal influenza vaccine—like flipping a coin.

After receiving the investigational vaccine, participants must enter information about any influenza symptoms they have had into a symptom-reporting electronic diary, or eDiary. For the first 7 days after the vaccination, participants will be asked to report symptoms daily. Then for the next 6 months, participants will report symptoms twice a week. For the following 6 months, participants will report symptoms once a week. 

Participants will be closely monitored by the clinical study team for any side effects.  

Insurance is not needed to take part in the Glow Study. Compensation for the participant’s study-related time may be available. 


The Glow Trial is assessing the safety and efficacy of an investigational vaccine, called mRNA-1010, aimed at preventing seasonal influenza in adults over 50. This investigational vaccine is based on mRNA technology. An investigational vaccine is a vaccine not yet approved by a country’s drug regulatory agency.

Flu is estimated to cause 3 to 5 million cases of severe illness and up to 650,000 deaths each year. Current flu vaccinations rarely exceed 60% overall effectiveness. 


The Glow Study is assessing the safety and efficacy of an investigational vaccine, called mRNA-1010, aimed at preventing seasonal influenza in adults over 50. This investigational vaccine is based on mRNA technology. An investigational vaccine is a vaccine not yet approved by a country’s drug regulatory agency.

Flu is estimated to cause 3 to 5 million cases of severe illness and up to 650,000 deaths each year. Current flu vaccinations rarely exceed 60% overall effectiveness. 


A Clinical Trial of a Seasonal Influenza (Flu) Vaccine for Adults Over 50

A Clinical Study of a Seasonal Influenza (Flu) Vaccine for Adults Over 50

Cytomegalovirus (CMV) is a leading cause of birth defects around the world. CMV is a common but often overlooked viral infection that can have a lifelong impact.  CMV usually goes unnoticed or only causes mild symptoms in most people, however, once CMV is in the body, it stays there for life. At certain times in a person's life, such as pregnancy, CMV can reactivate. An active CMV infection during pregnancy can put the unborn baby at risk of birth defects. These include hearing loss, vision loss, or cerebral palsy, which can lead to long-term disability or, in severe cases, death. Currently, there is no approved vaccine against CMV.

Have participated in another trial within a month of the Screening Visit  

Have participated in another study within a month of the Screening Visit  

Kids and teens between 9–15 years of age OR females
between 16–25 years of age

Able to follow instructions to participate in the clinical trial

Able to follow instructions to participate in the clinical study

The CMVibe Trial will have 2 parts. Part 1 of the CMVibe trial is currently enrolling participants. 

In Part 1, the clinical trial staff will evaluate different dose levels of the trial vaccine in children ages 9–15 years and compare this age group’s reactions to those of females ages 16–25 years. 

-	All participants will get a total of 3 injections of the trial vaccine in the upper arm during the first 6 months of the clinical trial. 
-	The group of females ages 16 to 25 will all receive the same dose level of mRNA-1647 that has already been studied in people in their age group.
-	Participants ages 9 to 15 will receive 1 of 3 dose levels of mRNA-1647: low, medium, or high. Because this is the first time the trial vaccine is being given to kids and teens, we will do this trial in 3 steps to ensure maximum safety, starting with the lowest dose first. Once the dose is set for each participant, the same dose level will be given to them in all 3 injections.  

In Part 2, the clinical trial staff will compare the dose level selected in Part 1 against a placebo. Part 2 will only enroll children ages 9–15. 

-	All participants will get a total of 3 injections of the trial vaccine in the upper arm during the first 6 months of the clinical trial. 
-	Participants have a chance of receiving either the mRNA-1647 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against CMV. Participants will not know whether they receive the investigational vaccine or placebo.

The total length of participation in the CMVibe Trial is 18 months and includes up to 10 telephone calls and 12 in-person clinical trial site visits.

During the trial site visits, participants will answer questions about health, diet, and quality of life. The trial team will also perform physical exams and blood sample collection. Throughout the trial, participants will use an electronic diary (eDiary) to record any symptoms they might experience after their injection.  During the phone call appointments, the trial team will check how the participant is feeling and ask for updates on their health.  

Participants will be closely monitored by the clinical trial team for any side effects.  

Insurance is not needed to take part in the CMVibe Trial. Compensation for the participant’s trial-related time may be available. 

The CMVibe Study will have 2 parts. Part 1 of the CMVibe study is currently enrolling participants. 

In Part 1, the clinical study staff will evaluate different dose levels of the study vaccine in children ages 9–15 years and compare this age group’s reactions to those of females ages 16–25 years. 

-	All participants will get a total of 3 injections of the study vaccine in the upper arm during the first 6 months of the clinical study. 
-	The group of females ages 16 to 25 will all receive the same dose level of mRNA-1647 that has already been studied in people in their age group.
-	Participants ages 9 to 15 will receive 1 of 3 dose levels of mRNA-1647: low, medium, or high. Because this is the first time the study vaccine is being given to kids and teens, we will do this study in 3 steps to ensure maximum safety, starting with the lowest dose first. Once the dose is set for each participant, the same dose level will be given to them in all 3 injections.  

In Part 2, the clinical study staff will compare the dose level selected in Part 1 against a placebo. Part 2 will only enroll children ages 9–15. 

-	All participants will get a total of 3 injections of the study vaccine in the upper arm during the first 6 months of the clinical study. 
-	Participants have a chance of receiving either the mRNA-1647 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against CMV. Participants will not know whether they receive the investigational vaccine or placebo.

The total length of participation in the CMVibe Study is 18 months and includes up to 10 telephone calls and 12 in-person clinical study site visits.

During the study site visits, participants will answer questions about health, diet, and quality of life. The study team will also perform physical exams and blood sample collection. Throughout the study, participants will use an electronic diary (eDiary) to record any symptoms they might experience after their injection.  During the phone call appointments, the study team will check how the participant is feeling and ask for updates on their health.  

Participants will be closely monitored by the clinical study team for any side effects.  

Insurance is not needed to take part in the CMVibe Study. Compensation for the participant’s study-related time may be available. 

The purpose of the CMVibe Trial is to determine which dose level of the trial vaccine (called mRNA-1647) is most effective at preventing cytomegalovirus (CMV) in people 9 to 15 years of age. Dose level is the amount of trial vaccine being tested. The dose levels being evaluated in this trial are based on dose levels already studied in adults. To understand more about the trial vaccine’s effects in kids and teens ages 9 to 15, medical researchers are comparing this age group’s reactions to those of participants ages 16 to 25. 

Participation in the CMVibe Trial lasts approximately 18 months, including up to 10 telephone calls and 12 in-person clinical trial site visits.


The purpose of the CMVibe Study is to determine which dose level of the study vaccine (called mRNA-1647) is most effective at preventing cytomegalovirus (CMV) in people 9 to 15 years of age. Dose level is the amount of study vaccine being tested. The dose levels being evaluated in this study are based on dose levels already studied in adults. To understand more about the study vaccine’s effects in kids and teens ages 9 to 15, medical researchers are comparing this age group’s reactions to those of participants ages 16 to 25. 

Participation in the CMVibe Study lasts approximately 18 months, including up to 10 telephone calls and 12 in-person clinical study site visits.


A Clinical Trial of Cytomegalovirus (CMV) Vaccine in Participants 9 to 25 Years of Age

A Clinical Study of Cytomegalovirus (CMV) Vaccine in Participants 9 to 25 Years of Age

RSV is a virus that can cause infections of the lungs and respiratory tract. Symptoms can be like a cold, and may include a runny nose, sore throat, cough, and headache. RSV can lead to serious conditions like pneumonia, which is more common in younger children and older adults.

Once participants join the observational ROSE study, no additional action is needed from them.
Participants will give permission for the study team to collect personal health-related data like past and present health conditions, medical treatment information, hospital stay data, and costs of healthcare. This data will be gathered from medical providers including doctors’ offices, hospitals, pharmacies, and lab companies. 
Participants’ health-related data will be kept private using a process called tokenization. This replaces your personal information with a unique string of letters, numbers, or symbols called a token.
Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time.

Once participants join the observational ROSE study, no additional action is needed from them.

Participants will give permission for the study team to collect personal health-related data like past and present health conditions, medical treatment information, hospital stay data, and costs of healthcare. This data will be gathered from medical providers including doctors’ offices, hospitals, pharmacies, and lab companies. 

Participants’ health-related data will be kept private using a process called tokenization. This replaces your personal information with a unique string of letters, numbers, or symbols called a token.

Insurance is not needed to participate, and qualified participants will receive payment for their study-related time.

Participants enrolled in the mRNA-1345-P301 [ConquerRSV Trial](https://conquerrsv.com/) have the option to participate in the mRNA-1345-P901 ROSE observational study to allow collection of their health-related data for future research.

Participants’ collected health-related data will help researchers better understand respiratory syncytial virus (RSV) and how well investigational RSV vaccines work. The study will also help gather research on other lung diseases, such as COVID-19 and influenza (flu).

Participants enrolled in the mRNA-1345-P301 [ConquerRSV Study](https://conquerrsv.com/) have the option to participate in the mRNA-1345-P901 ROSE observational study to allow collection of their health-related data for future research.

Participants’ collected health-related data will help researchers better understand respiratory syncytial virus (RSV) and how well investigational RSV vaccines work. The study will also help gather research on other lung diseases, such as COVID-19 and influenza (flu).

An Observational Study for Participants Previously Enrolled in the ConquerRSV Trial

An Observational Study for Participants Previously Enrolled in the ConquerRSV Study

Influenza, commonly referred to as “the flu” is a virus that can cause infections of the lungs and respiratory tract. Flu is estimated to cause 3 to 5 million cases of severe illness and up to 650,000 deaths each year.

Respiratory syncytial virus (RSV) is a virus that can cause infections of the lungs and respiratory tract. Symptoms can be like a cold and may include a runny nose, sore throat, cough, and headache. RSV can lead to serious conditions like pneumonia, especially for younger children and older adults.

COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus. Common symptoms are similar to the flu and include fever, cough, and tiredness. More serious symptoms include difficulty breathing and, in rare cases, death. The World Health Organization declared COVID-19 a pandemic in March 2020. Since that time, there have been more than 500 million cases and 6.2 million deaths worldwide.


- Have a pre-existing medical condition that is not stable


- Have participated in another clinical trial within the past month


- Have participated in another clinical study within the past month


- Be fully vaccinated for COVID-19 (with or without a booster) for at least 4 months

Participation in the Trio P101 Trial will last approximately 13 months and includes 7 visits to a trial site and up to 8 safety phone calls. 
Participants will be given 1 injection of an investigational vaccine in the upper arm.

Participants will use an electronic diary (eDiary) through an app on their smartphone or a provided device, to record how they are feeling for 7 days after they receive the investigational vaccine.
Participants will have follow-up visits at their clinical trial site over the course of the trial for tests that will show if the investigational vaccine is working.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.


Participation in the Trio P101 Study will last approximately 13 months and includes 7 visits to a study site and up to 8 safety phone calls. 
Participants will be given 1 injection of an investigational vaccine in the upper arm.

Participants will use an electronic diary (eDiary) through an app on their smartphone or a provided device, to record how they are feeling for 7 days after they receive the investigational vaccine.
Participants will have follow-up visits at their clinical study site over the course of the study for tests that will show if the investigational vaccine is working.

Insurance is not needed to participate, and qualified participants will receive payment for their study-related time and travel.


The purpose of this clinical trial is to assess the safety of and immune responses to investigational vaccines aimed at preventing 3 common viruses: flu, respiratory syncytial virus (RSV), and COVID-19 in adults 50 to 75 years of age.
Flu, RSV, and COVID-19 are all respiratory illnesses. Flu is caused by the influenza virus. COVID-19 is caused by the SARS-CoV-2 virus. You may be less familiar with RSV, which is one of the most common causes of lower respiratory tract infections worldwide.
In this trial, 5 different investigational vaccines will be evaluated. All participants will be randomly assigned to one of the groups in the trial, which will determine which investigational vaccine and dose each participant receives. Each participant will only receive 1 investigational vaccine. In this clinical trial, the investigational vaccines are:

- mRNA-1010: An investigational vaccine for the prevention of flu
- mRNA-1045: An investigational combination vaccine for the prevention of flu and RSV
- mRNA-1273.214: An investigational booster vaccine for the prevention of COVID-19 and some of its variants
- mRNA-1345: An investigational vaccine for the prevention of RSV
- mRNA-1230: An investigational combination vaccine for the prevention of flu, RSV, and COVID-19


The purpose of this clinical study is to assess the safety of and immune responses to investigational vaccines aimed at preventing 3 common viruses: flu, respiratory syncytial virus (RSV), and COVID-19 in adults 50 to 75 years of age.
Flu, RSV, and COVID-19 are all respiratory illnesses. Flu is caused by the influenza virus. COVID-19 is caused by the SARS-CoV-2 virus. You may be less familiar with RSV, which is one of the most common causes of lower respiratory tract infections worldwide.
In this study, 5 different investigational vaccines will be evaluated. All participants will be randomly assigned to one of the groups in the study, which will determine which investigational vaccine and dose each participant receives. Each participant will only receive 1 investigational vaccine. In this clinical study, the investigational vaccines are:

- mRNA-1010: An investigational vaccine for the prevention of flu
- mRNA-1045: An investigational combination vaccine for the prevention of flu and RSV
- mRNA-1273.214: An investigational booster vaccine for the prevention of COVID-19 and some of its variants
- mRNA-1345: An investigational vaccine for the prevention of RSV
- mRNA-1230: An investigational combination vaccine for the prevention of flu, RSV, and COVID-19


A clinical trial of investigational flu, RSV, and COVID-19 vaccines for adults 50–75 years of age

A clinical study of investigational flu, RSV, and COVID-19 vaccines for adults 50–75 years of age

Cancer is a major public health problem and is the leading cause of death worldwide. Due to increased screening and targeted treatment regimens, there has been a trend over the past decade toward a slowing or halting in the progression of some highly preventable cancers (e.g. lung and skin cancers). However, there remains an unmet need for targeted anticancer therapies, especially for patients for whom current treatments have not been effective. 

Have confirmed locally advanced or metastatic cancer

- Includes: cutaneous melanoma, NSCLC, non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, MSS CRC, basal cell carcinoma, or triple-negative breast cancer
- Also includes: confirmed locally advanced or metastatic melanoma or NSCLC who have received previous checkpoint inhibitor therapy

Have experienced disease progression after receiving standard-of-care therapies or be intolerant to standard-of-care treatment

During the trial, participants will attend approximately 15 visits to the trial site over the course of approximately 3 years. This includes a 28-day screening period, a treatment period of approximately 6 months, a 90-day safety follow-up, and a 2-year follow-up period. 
Participants in this trial will be assigned to treatment groups, called Arms:

- Arm 1a
  - This group will aim to treat adults who have locally advanced or metastatic cancer (cutaneous melanoma, non-small-cell lung carcinoma [NSCLC], non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer [MSS CRC], basal cell carcinoma, or triple negative breast cancer) who have previously received treatment for their cancer.
  - Participants assigned to Arm 1a will receive the investigational treatment.
  - The goal of Arm 1a is to determine a safe dose of the investigational treatment.
- Arm 1b
  - This group will include adults who have locally advanced or metastatic melanoma or NSCLC who previously received immunotherapy (called checkpoint inhibitor therapy) for their cancer.
  - Participants assigned to Arm 1b will receive the investigational treatment in combination with pembrolizumab.
  - The goal of Arm 1b is to determine a safe dose of the investigational treatment in combination with pembrolizumab.
- Pharmacodynamic Arm
  - In addition to the goals of Arm 1b, researchers will also be evaluating how the investigational treatment and pembrolizumab effect the immune system and the cancer in a group called the Pharmacodynamic (PD) Arm.
  - Participants enrolled in the PD Arm will receive the investigational treatment and will also be asked to provide additional blood and tissue samples.

The investigational treatment will be administered as an intramuscular injection, while pembrolizumab will be administered as an intravenous infusion. Participants will be monitored at the trial site for 30 minutes after their assigned treatment administration.

Every clinical trial participant will receive the same level of quality care regardless of which treatment group they are assigned. 

Insurance is not needed to join this trial, and all trial-related medications are provided at no cost to participants.


During the study, participants will attend approximately 15 visits to the study site over the course of approximately 3 years. This includes a 28-day screening period, a treatment period of approximately 6 months, a 90-day safety follow-up, and a 2-year follow-up period. 
Participants in this study will be assigned to treatment groups, called Arms:

- Arm 1a
  - This group will aim to treat adults who have locally advanced or metastatic cancer (cutaneous melanoma, non-small-cell lung carcinoma [NSCLC], non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer [MSS CRC], basal cell carcinoma, or triple negative breast cancer) who have previously received treatment for their cancer.
  - Participants assigned to Arm 1a will receive the investigational treatment.
  - The goal of Arm 1a is to determine a safe dose of the investigational treatment.
- Arm 1b
  - This group will include adults who have locally advanced or metastatic melanoma or NSCLC who previously received immunotherapy (called checkpoint inhibitor therapy) for their cancer.
  - Participants assigned to Arm 1b will receive the investigational treatment in combination with pembrolizumab.
  - The goal of Arm 1b is to determine a safe dose of the investigational treatment in combination with pembrolizumab.
- Pharmacodynamic Arm
  - In addition to the goals of Arm 1b, researchers will also be evaluating how the investigational treatment and pembrolizumab effect the immune system and the cancer in a group called the Pharmacodynamic (PD) Arm.
  - Participants enrolled in the PD Arm will receive the investigational treatment and will also be asked to provide additional blood and tissue samples.

The investigational treatment will be administered as an intramuscular injection, while pembrolizumab will be administered as an intravenous infusion. Participants will be monitored at the study site for 30 minutes after their assigned treatment administration.

Every clinical study participant will receive the same level of quality care regardless of which treatment group they are assigned. 

Insurance is not needed to join this study, and all study-related medications are provided at no cost to participants.


The Mobilize Trial is a Phase 1/2 clinical trial evaluating the safety and anti-tumor activity of an investigational mRNA treatment in adults who have select advanced solid tumor cancer. The investigational treatment, called mRNA-4359, is being evaluated on its own and in combination with pembrolizumab (an approved immunotherapy treatment, also known as KEYTRUDA®).

In this trial, Moderna is researching the use of mRNA-4359 to see if it will instruct the body to target certain immune cells and cancer cells to slow or prevent cancer growth. Cancer treatments based on mRNA technology could potentially provide several benefits compared to the current standard-of-care treatments, including minimizing the possibility of long-term side effects.


The Mobilize Study is a Phase 1/2 clinical study evaluating the safety and anti-tumor activity of an investigational mRNA treatment in adults who have select advanced solid tumor cancer. The investigational treatment, called mRNA-4359, is being evaluated on its own and in combination with pembrolizumab (an approved immunotherapy treatment, also known as KEYTRUDA®).

In this study, Moderna is researching the use of mRNA-4359 to see if it will instruct the body to target certain immune cells and cancer cells to slow or prevent cancer growth. Cancer treatments based on mRNA technology could potentially provide several benefits compared to the current standard-of-care treatments, including minimizing the possibility of long-term side effects.


A Clinical Trial of a Cancer Treatment for Adults with Solid Tumor Cancers

A Clinical Study of a Cancer Treatment for Adults with Solid Tumor Cancers

A Clinical Trial of a Seasonal Influenza Vaccine in Adults

A Clinical Study of a Seasonal Influenza Vaccine in Adults

A Clinical Trial of a Seasonal Influenza (Flu) Vaccine for Adults

A Clinical Study of a Seasonal Influenza (Flu) Vaccine for Adults

A Clinical Trial of a Combination COVID-19 and Influenza Vaccine for Adults

A Clinical Study of a Combination COVID-19 and Influenza Vaccine for Adults

A Post-Marketing Safety Study of an Approved COVID-19 Vaccine

A Study to Compare COVID-19 Vaccines in Immunocompromised Adults

A Clinical Trial of a COVID-19 Booster Vaccine for Adults

A Clinical Study of a COVID-19 Booster Vaccine for Adults

A Clinical Trial of an Respiratory Syncytial Virus (RSV) Vaccine for Adults Over 50

A Clinical Study of an Respiratory Syncytial Virus (RSV) Vaccine for Adults Over 50

An Extension Study for Participants Previously Enrolled in the mRNA-3705 MMA Phase 1 Landmark Study

An Extension Study for Participants Previously Enrolled in the mRNA-3927 Propionic Acidemia Phase 1 Paramount Study

A Clinical Trial of mRNA Vaccines in Adults

A Clinical Study of mRNA Vaccines in Adults

Be currently taking any investigational or approved treatments for COVID-19 

Have tested positive for COVID-19 or been in contact with anyone diagnosed with COVID-19 within 2 weeks prior to vaccine administration 

Have participated in another COVID-19 trial in the past month 

Have participated in another COVID-19 study in the past month 

Participation in the KidCOVE Study lasts up to 17 months and includes phone calls, telemedicine visits, and up to eight visits to the study site.

- In Part 1 and 2 of the study, participants will be given two injections in the upper arm or thigh—about 28 days apart. Participants in these groups have a chance of receiving either the mRNA-1273 study vaccine or the placebo. By using a placebo, medical researchers are able to understand if the study vaccine is effective in preventing COVID-19.
- In Part 3 of the study, participants ages 6 years to < 12 years will be given three injections in the upper arm — the first two doses will be about 28 days apart, and the third dose will be given approximately 4 months after the second dose. All participants in this group will receive the mRNA-1273 investigational vaccine.
- Each part of the study may run in parallel or may close at different times, meaning eligibility may vary based on age and location.
- Participants and their caregivers will be asked to return to the study site up to seven times depending on their enrollment assignment.
- Participants and their caregivers will have two telemedicine visits with the study doctor after each injection, and then monthly after that to monitor for COVID-19 symptoms. During these phone calls, the study doctor and medical staff will check how the participant is feeling and ask for updates on their health.
- Caregivers of participants will be asked to use an eDiary app on your smartphone or a provided smartphone to report any COVID-19 symptoms the participants experience.
- Participants will be closely monitored by the study team if any symptoms of COVID-19 are reported at any time throughout their participation.

The study doctor and medical staff will talk to participants and their caregivers about additional medical support that they will receive if they experience COVID-19 symptoms at any time while in this clinical trial. Insurance is not needed to join this clinical trial, and compensation for your time will be available.

Participation in the KidCOVE Study lasts up to 17 months and includes phone calls, telemedicine visits, and up to eight visits to the study site.

- In Part 1 and 2 of the study, participants will be given two injections in the upper arm or thigh—about 28 days apart. Participants in these groups have a chance of receiving either the mRNA-1273 study vaccine or the placebo. By using a placebo, medical researchers are able to understand if the study vaccine is effective in preventing COVID-19.
- In Part 3 of the study, participants ages 6 years to < 12 years will be given three injections in the upper arm — the first two doses will be about 28 days apart, and the third dose will be given approximately 4 months after the second dose. All participants in this group will receive the mRNA-1273 investigational vaccine.
- Each part of the study may run in parallel or may close at different times, meaning eligibility may vary based on age and location.
- Participants and their caregivers will be asked to return to the study site up to seven times depending on their enrollment assignment.
- Participants and their caregivers will have two telemedicine visits with the study doctor after each injection, and then monthly after that to monitor for COVID-19 symptoms. During these phone calls, the study doctor and medical staff will check how the participant is feeling and ask for updates on their health.
- Caregivers of participants will be asked to use an eDiary app on your smartphone or a provided smartphone to report any COVID-19 symptoms the participants experience.
- Participants will be closely monitored by the study team if any symptoms of COVID-19 are reported at any time throughout their participation.

The study doctor and medical staff will talk to participants and their caregivers about additional medical support that they will receive if they experience COVID-19 symptoms at any time while in this clinical study. Insurance is not needed to join this clinical study, and compensation for your time will be available.

The primary purpose of the KidCOVE Study is to test the safety and effectiveness of the study vaccine, called mRNA-1273, that may protect children between the ages of 6 months to < 12 years from getting sick if they come into contact with SARS-CoV-2, which causes COVID-19. Moderna will be recruiting multiple age groups from 6 months to < 12 years and staggering the recruitment of each group. The goal of this study is to evaluate the safety and effectiveness of different dose amounts and regimens, including a three-dose regimen in children 6 to < 12 years. Please be aware that there may be a delay in hearing from a study site, or the site near you may no longer be recruiting in a specific age group.

A Clinical Trial of a COVID-19 Vaccine for Children

A Clinical Study of a COVID-19 Vaccine for Children

RSV and hMPV cause infections of the lungs and respiratory tract. Globally, these viruses are responsible for millions of respiratory tract infections and hospitalizations, and young children are particularly susceptible to serious infection. Despite this high disease burden, there is currently limited information on treatments for RSV and hMPV. In 2019, RSV was associated with over 100,000 deaths of children across the world. Globally, an estimated 11.1 million acute lower respiratory infections, 502,000 hospital admissions, and 11,300 deaths were attributed to hMPV in 2018, with those under 12 months of age being disproportionately impacted.

Have a known history of RSV or hMPV infection in the past 3 months

Have parents/guardians willing and able to attend all trial visits

Participation in the Rhyme Trial will last approximately 16–24 months and includes up to 9 in-person visits (at a local clinical trial site or at the participant’s home) and up to 18 phone calls.

Your child will be given 3 injections in the upper arm or leg, each 56 days apart. They will be chosen at random to receive either mRNA-1345, mRNA-1365, or a placebo. All trial participants will receive the same level of quality care regardless of whether they are assigned to an investigational vaccine or the placebo.

You will be asked to use an eDiary app on your smartphone or a provided smartphone to report any side effects your child might experience for 6 days after each injection.

Your child will be closely monitored by the trial team if any symptoms of RSV or hMPV (for example, coughs and 'colds') are reported at any time throughout their participation.

The purpose of the Rhyme Trial is to evaluate the immune response to 2 investigational vaccines and also assess their safety. These investigational vaccines, called mRNA-1345 and mRNA 1365, are being evaluated to see if they will protect against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in children ages 5–23 months.

The investigational vaccines being evaluated in this clinical trial are not made from a weakened or killed virus. Instead, they include a man-made version of a molecule called messenger ribonucleic acid (mRNA), which is thought to provide the body with instructions on how to potentially defend against a virus. mRNA makes a harmless protein that replicates a virus, triggering the body’s immune system to create antibodies. Through this natural process, the immune system may create the antibodies it needs if it ever encounters the actual RSV or hMPV viruses. It is hoped that these antibodies will be able to fight the viruses.

A clinical trial of vaccines for RSV and hMPV in babies and young children

Herpes zoster (HZ), also known as shingles, is caused by the varicella-zoster virus, the virus that also causes chickenpox. The majority of shingles cases resolve in three to five weeks. However, the most common complication of HZ is postherpetic neuralgia (PHN), characterized by the persistence of pain for longer than three months following the onset of HZ rash. Affected individuals may experience pain described as stabbing, burning, or throbbing. PHN usually resolves within a year, but in rare cases, symptoms can last for many years. The Centers for Disease Control estimates that HZ affects more than 1 million people per year in the United States and that approximately 1 in 3 persons will develop HZ in their lifetime. The risk of HZ increases significantly with age, with about half of cases occurring in individuals over the age of 60.

Have had shingles within the past 10 years

Have been vaccinated against chickenpox or shingles previously

Participation in the Zone Trial will last approximately 15 months and includes 10 visits to a trial site and up to 8 safety phone calls.

Participants will be given 2 injections in the upper arm and will be chosen at random to receive either the investigational vaccine or the existing shingles vaccine. By comparing the investigational vaccine to one that is already approved and circulated, medical researchers can better understand how well the investigational vaccine works.

All trial participants will receive the same level of quality care regardless of whether they are assigned to the investigational vaccine or the currently available shingles vaccine.

Participants will be asked to use an eDiary app on their smartphone or a provided smartphone to report any side effects they might experience for 1 week after each injection.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.

The purpose of the Zone Trial is to evaluate the safety of and immune response to an investigational vaccine, called mRNA-1468, for protecting against herpes zoster (HZ), otherwise known as shingles, in adults ages 50 and up.

Varicella-zoster virus, or VZV, is the virus that causes chickenpox. If an individual has had chickenpox in the past, it is possible for the VZV virus to reactivate in their body and cause shingles. This is most common in adults over the age of 50, and often manifests as a burning or throbbing rash that usually lasts for a few weeks.

According to a recent study published in Clinical Infectious Diseases, the shingles vaccine that is currently available in the US is over 85% effective. Despite this, only a fraction of eligible individuals have received both doses. Due to the low percentage of vaccinated individuals, a high number of cases is estimated to occur within the next decade, so there is a need for wider distribution of a shingles vaccine.

A clinical trial of a shingles vaccine for adults over 50

Seasonal influenza, also known as the seasonal flu, is a respiratory illness caused by the influenza virus. This virus infects the lungs and breathing passages and is easily spread from person to person. Every year, seasonal influenza causes 3 to 5 million cases of severe illness and up to 650,000 deaths worldwide. Seasonal influenza more severely affects people 65 years of age and older.

COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus. Common symptoms are similar to the flu and include fever, cough, and tiredness. More serious symptoms include difficulty breathing and, in rare cases, death. The World Health Organization declared COVID-19 a pandemic in March 2020. Since that time, there have been more than 500 million cases and 6.2 million deaths worldwide.

Have received a COVID-19 vaccine (primary series or booster) within the past 4 months

Have received a seasonal flu vaccine within the past 5 months

Have completed the 2-dose COVID-19 vaccine primary series

Participation in the Duo P101 Trial will last approximately 7 months and includes 5 visits to a trial site and up to 4 safety phone calls.

Participants will be given 1 injection in the upper arm.

You will be randomly assigned to a certain dose of 1 of the 3 investigational combination vaccines (mRNA-1083.1, mRNA-1083.2, mRNA-1083.3) or 1 of the 6 active controls (mRNA-1010.4, mRNA-1283.222, Spikevax Bivalent, mRNA-1010, Fluarix, Fluzone HD). In this clinical trial, the active controls are COVID-19 and seasonal flu vaccines that are either approved for use, previously tested, or currently under investigation. There are no placebos in this trial.

All trial participants will receive the same level of quality care regardless of which vaccine they receive.

Participants will be asked to use an eDiary app on their smartphone (or a provided device) to report any side effects they might experience every day for 7 days after receiving the injection.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.


The Duo P101 Trial will assess the safety of an investigational combination vaccine, called mRNA-1083, aimed at preventing seasonal flu and COVID-19 infections in adults ages 18 to 79.

Seasonal flu and COVID-19 are respiratory illnesses; seasonal flu is caused by the influenza virus, and COVID-19 is caused by the SARS-CoV-2 virus. These viruses infect the lungs and breathing passages and are easily spread from person to person. Both illnesses more severely affect those over 65.

mRNA-1083 is a messenger RNA (mRNA) vaccine. mRNA vaccines aim to teach the body how to make a specific protein that may potentially help your immune system prevent or treat certain diseases. The hope is that the vaccine trains your immune system cells to "remember" these proteins and help your body quickly protect against the strain of infection if exposed in the future. 


A Clinical Trial of a Combination Seasonal Flu and COVID-19 Vaccine for Adults

Seasonal influenza, also known as the seasonal flu, is a respiratory illness caused by the influenza virus. This virus infects the lungs and breathing passages and is easily spread from person to person. Every year, seasonal influenza causes 3 to 5 million cases of severe illness and up to 650,000 deaths worldwide. Seasonal influenza more severely affects people 65 years of age and older.

- Have received a seasonal flu vaccine within the past 6 months


- Be 50–75 years of age 
- Be in generally good health 


Participation in the Ember Trial will last approximately 7 months and includes at least 5 visits to a trial site and 5 safety phone calls. 

Participants will be given 1 injection in the upper arm.

Participants will be randomly assigned to a certain dose of 1 of the 3 investigational flu vaccines (called mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) or the control (mRNA-1010). The control is an investigational mRNA vaccine for seasonal flu that is being evaluated in other Moderna trials. 

This is an open-label clinical trial, which means you will be told which investigational vaccine you are given. 

All trial participants will receive the same level of quality care regardless of which vaccine they receive.

Participants will be asked to use an eDiary app on their smartphone (or a provided device) to report any side effects they might experience for the first 7 days after injection.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.


The Ember Trial will assess the safety of and the body’s immune responses to 3 investigational vaccines aimed at preventing the flu. Your participation in this clinical trial will help advance research of an investigational mRNA flu vaccine and potentially support investigational vaccine development for other infectious diseases. 

Currently available flu vaccines are designed to protect against the influenza viruses that health experts predict will be the most common during the upcoming season. However, they take several months to make, and their effectiveness depends on how well the predicted flu strains match the ones that actually circulate.

The investigational vaccines being studied are mRNA vaccines. mRNA vaccines aim to teach the body how to make a specific protein that may potentially help your immune system prevent or treat certain diseases. The hope is that the vaccine trains your immune system cells to “remember” these proteins and help your body protect against the strain of infection if exposed in the future. 
